Tonix Pharmaceuticals Holding Corporation (TNXP) Quote

TNXP....................................https://stockcharts.com/h-sc/ui?s=TNXP&p=W&b=5&g=0&id=p86431144783

Good price movement today. Just getting started

TNXP...Great news...Volume...PPS DOWN..dilution or extreme shorting? Heading back to PPS before 1 for 32 RS on 6/10

TNXP...Great news...Volume...PPS DOWN..dilution or extreme shorting? Heading back to PPS before 1 for 32 RS on 6/10

Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program.

https://finance.yahoo.com/news/tonix-pharmaceuticals-awarded-34-million-120000714.html

BOOM! .99 pre-market

An Afternoon / AH run back to a buck would be a nice way to end the week.

TNXP new 52 week low

The dip is in dude!!! Now we can ripppp the shit

In at .77

Re-entered on the dip. Loaded as low as .81

Another Good News just came out today --- "Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024"

https://finance.yahoo.com/news/tonix-pharmaceuticals-presents-vaccine-platform-120000146.html

CHATHAM, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data presented at an oral Keynote Talk at the Vaccine Congress 2024 held June 24-25, 2024 in Prague, Czech Republic. A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

The presentation titled, “A New Live Virus, One Dose Vaccine Platform for Mpox, Smallpox and COVID-19”, detailed the Company’s vaccine platform, including TNX-801 (horsepox, live virus) vaccine for preventing mpox (formerly known as monkeypox) and smallpox and TNX-1800 (horsepox expressing SARS-CoV-2 spike protein) for protecting against COVID-19. TNX-801 and TNX-1800 are live replicating attenuated vaccines based on horsepox that are believed to provide immune protection with better tolerability than modern vaccinia viruses. In the presentation, Tonix highlighted positive preclinical efficacy data, demonstrating that TNX-801 protected non-human primates against lethal challenge with intratracheal Clade 1 monkeypox virus3. After a single dose vaccination, TNX-801 prevented clinical disease and lesions and also decreased shedding in the mouth and lungs of non-human primates. These findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner’s vaccinia vaccine, which eradicated smallpox and kept mpox out of the human population.

“We are excited for the prospects of our live virus vaccine platform and look forward to advancing development for our vaccine candidates to prevent mpox, smallpox, COVID and other infectious diseases,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “TNX-801 combines immune protection with improved tolerability compared to other vaccines based on orthopoxviruses. TNX-801 is administered with a single dose which has advantages over two-dose regimens. We believe TNX-801 can be rapidly scaled up for manufacturing and can be distributed and stored without a costly and cumbersome ultra-cold supply chain. TNX-801 also has the potential to be used as a viral vector platform, for which recombinant versions can be developed to protect against other infectious diseases. Tonix developed TNX-1800 as a vaccine to protect against COVID-19. We are excited that TNX-1800 was selected for the U.S. National Institute of Health’s (NIH’s) Project NextGen and we look forward to providing updates on the program.”

The presentation noted that the global mpox outbreak, which commenced in 2022, has affected over 90,000 persons in countries where mpox had previously not been endemic, including Europe and the US. The spread of Clade IIb strain mpox in 2022 underscores the pandemic potential of mpox. Unlike Clade IIb mpox, the Clade I strain of mpox remains restricted to several Central African countries, including the Democratic Republic of the Congo, where it is currently endemic. Clade I mpox is typically associated with higher case fatality rates than Clade IIb mpox. According to the U.S. Centers for Disease Control and Prevention (CDC), and other experts, there is a significant risk that the deadlier Clade I strain may appear in the U.S.1,4.

Further, the presentation noted that the Bipartisan Commission on Biodefense recently highlighted the renewed dual threats of both a more virulent mpox epidemic as well as smallpox re-introduction from lab accidents or bad actors, while the National Academies of Science, in its review of smallpox preparedness, highlighted the need for new single dose vaccines against smallpox5,6.

The keynote presentation also included preclinical data for TNX-1800, demonstrating immunity and tolerability7,8. TNX-1800 was selected by the NIH’s Project NextGen for inclusion in clinical trials as part of a select group of next generation COVID-19 vaccine candidates with the intent to identify promising vaccine platforms. NIH plans to conduct a Phase 1 trial and cover the full cost, while Tonix provides the vaccine candidate.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya**, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

**Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

1McQuiston JH, et al. U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo. 2024, MMWR Morb Mortal Wkly Rep: United States. p. 435-440
2CDC. 2022-2023 Mpox: US Map and Case Count. https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html
3Noyce RS, et al. Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356. PMID: 36851570; PMCID: PMC9965234
4World Health OrganizationSAGE meeting highlights on updated mpox vaccine recommendations. 2024, March
5Bipartisan Commission on Biofence. Box the Pox: Redicing the risk of Smallpox and Other Orthopoxviruses, Washington:2024
6U.S. National Academies of Science. Future State of Smallpox Medical Countermeasures. Washington:2024
7Awasthi M, et al. Viruses. 2023 Oct 21;15(10):2131. doi: 10.3390/v15102131. PMID: 37896908; PMCID: PMC10612059.
8Awashti AM et al Vaccines (Basel). 2023 Nov 2;11(11):1682. doi:10.3390/vaccines11111682.PMID: 38006014

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

TNXP hit a New High $1.49 on June 20's After-Hours session which is just seven cents below June 13's Premarket-High $1.56!

This Diamond-In-Rough will Easily And Quickly surge over its previous Bottoms area $3.2 ~ $3.84 and test May 17's High $6.72 again just based on its Huge-Positive Book Value alone!

TNXP has Shocking-High Positive Book Value (BV) --- $36.22 a share which is 30.44 Times of current Super-Ridiculous-Low price $1.19!

TNXP has Huge Positive Cash Value (CV) --- $2.36 a share which is 2.02 Times of Super-Ridiculous-Low yesterday's low $1.17!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

Last January it did Quickly run 5.2-Bagger --- see the first chart below!

Yes, another Good News came out today --- "Peering Into Tonix Pharmaceuticals's Recent Short Interest"!

BENZINGA 12:45 PM ET 6/24/2024

Tonix Pharmaceuticals's (TNXP) short percent of float has risen 3126.83% since its last report. The company recently reported that it has 789 thousand shares sold short, which is 26.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.

Why Short Interest Matters
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

See Also: List of the most shorted stocks

Tonix Pharmaceuticals Short Interest Graph (3 Months)
short_fig

As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals(TNXP) has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

According to Benzinga Pro, Tonix Pharmaceuticals's(TNXP) peer group average for short interest as a percentage of float is 2.05%, which means the company has more short interest than most of its peers.

Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Easy to surge back to its last-month-high $6.72 (on May 17, 2024) again based on its Huge-Positive BV --- $36.22 a share!

Shorts out of ammo dudes!!!

TNXP hit a New High $1.49 Last evening which is just seven cents below June 13's Premarket-High $1.56!

Another Good News yesterday, a Big Fund company (L1 Capital Global Opportunities Master Fund, Ltd.) owns 10% of TNXP --- see the first link below!

https://www.otcmarkets.com/filing/html?id=17631170&guid=GkO-knhCSDkOvch

FDA-Drug-Approving Good News last evening --- see the two links below!

https://ih.advfn.com/stock-market/NASDAQ/tonix-pharmaceuticals-TNXP/stock-news/94077029/tonix-pharmaceuticals-announces-positive-pre-nda-c
https://www.otcmarkets.com/filing/html?id=17629870&guid=GkO-knhCSDkOvch

As soon as the coming Monday (June 24) this Diamond-In-Rough will surge over its previous Bottoms area $3.2 ~ $3.84 and test May 17's High $6.72 again...

TNXP has Shocking-High Positive Book Value (BV) --- $36.22 a share which is 27 Times of current Super-Ridiculous-Low price $1.35!

TNXP has Huge Positive Cash Value (CV) --- $2.36 a share which is 1.72 Times of Super-Ridiculous-Low yesterday's high $1.3725!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

Last January it did Quickly surge 5.2-Bagger --- see the first chart below!

Another Good News today --- see the link below! Hopefully the company could issue a Very Good News in the coming days...

https://ih.advfn.com/stock-market/NASDAQ/tonix-pharmaceuticals-TNXP/stock-news/94077029/tonix-pharmaceuticals-announces-positive-pre-nda-c

TNXP did surge to $1.56 on June 14's Premarket session and today it bounced up to $1.3725 so far!

TNXP has Shocking-High Positive Book Value (BV) --- $36.22 a share which is 27 Times of current Super-Ridiculous-Low price $1.35!

TNXP has Huge Positive Cash Value (CV) --- $2.36 a share which is 2.1 Times of Super-Ridiculous-Low today's low $1.15!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

Last January it did Quickly surge 5.2-Bagger --- see the first chart below!

Huge Price Gap ($8.32 ~ $6.72) will be filled up very soon from the second chart below!

In fact, its NASDAQ EV peer (KXI?) had already soared 5.66-Bagger to $0.6 from $0.1061 last month!

More FDA News dude!!!!
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
June 20 2024 - 8:00AM


Share On Facebook

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced receipt of the formal minutes from a recent pre-New Drug Application (NDA) Type-B Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA) for Tonmya™ for the management of fibromyalgia. The purpose of the meeting was to seek alignment and agreement with the FDA on key CMC topics to support a planned NDA submission for Tonmya for the management of fibromyalgia. Based on formal written feedback, the Company believes it is aligned with the FDA on key topics, including proposed drug substance and drug product commercial specifications, shelf life assignment, manufacturing and commercial drug packaging.
In addition, the Company has completed the second and final pre-NDA meeting for Tonmya with the FDA and discussed nonclinical, clinical pharmacology and clinical matters. The Company awaits formal minutes after which it expects to announce the results of that meeting. The Company remains on track to submit the NDA for Tonmya for the management of fibromyalgia to the FDA in the second half of 2024.

“We remain encouraged and excited about the prospect of bringing the first new treatment to market for fibromyalgia patients in over a decade, and this encouraging meeting with the FDA is an important milestone as we head into the final stages of completion of the NDA package,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “During the pre-NDA CMC meeting, the FDA affirmed alignment with Tonix on CMC content and commercial strategy for Tonmya, and we are very appreciative of the FDA’s guidance as we prepare for our NDA submission. We are currently actively preparing a dual manufacturing launch strategy with global contract development and manufacturing organization (CDMO) Almac Pharma Services and another CDMO.”

About Fibromyalgia

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6 million to 12 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

About Tonmya* (also known as TNX-102 SL)

Tonmya is a centrally acting, non-opioid, non-addictive, bedtime medication. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for the management of fibromyalgia. In December 2023, the company announced highly statistically significant and clinically meaningful topline results in RESILIENT, the second pivotal Phase 3 clinical trial of Tonmya for the management of fibromyalgia. In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all six key secondary endpoints related to improving sleep quality, reducing fatigue and improving overall fibromyalgia symptoms and function. RELIEF, the first statistically significant Phase 3 trial of Tonmya in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010) and showed activity in key secondary endpoints.

*Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Another Good News today --- see the link below! Hopefully the company could issue a Very Good News in the coming days...

https://ih.advfn.com/stock-market/NASDAQ/tonix-pharmaceuticals-TNXP/stock-news/94061790/tonix-pharmaceuticals-presented-data-comparing-rea

TNXP did surge to $1.56 on June 14's Premarket session and it also bounced up to $1.32 on June 13's After-Hour session!

TNXP has Shocking-High Positive Book Value (BV) --- $36.22 a share which is 30 Times of current Super-Ridiculous-Low price $1.22!

TNXP has Huge Positive Cash Value (CV) --- $2.36 a share which is nearly TWICE of Super-Ridiculous-Low today's high $1.26!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

Last January it did Quickly surge 5.2-Bagger --- see the first chart below!

Huge Price Gap ($8.32 ~ $6.72) will be filled up very soon from the second chart below!

Rocket boosters about to all activate

Another Good News today --- see the link below!

https://ih.advfn.com/stock-market/NASDAQ/tonix-pharmaceuticals-TNXP/stock-news/94053738/tonix-pharmaceuticals-presented-poster-of-tonmya

TNXP did surge to $1.56 on June 14's Premarket session and it also bounced up to $1.32 on June 13's After-Hour session!

TNXP has Shocking-High Positive Book Value (BV) --- $36.22 a share which is over 32 Times of current Super-Ridiculous-Low price $1.13!

TNXP has Huge Positive Cash Value (CV) --- $2.36 a share which is TWICE of current Super-Ridiculous-Low daily-high $1.19!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

Last January it did Quickly surge 5.2-Bagger --- see the first chart below!

Huge Price Gap (up to $8.32) will be filled up very soon from the second chart below!

TNXP did surge to $1.56 in today's Premarket session and $1.32 in yesterday's After-Hour session after Good News (see the link below)! Last January it did Quickly surge 5.2-Bagger --- see the third chart below!

https://www.otcmarkets.com/filing/html?id=17619193&guid=cqQ-kamb8r4T4rh

This Hidden Gem is also at Hyper Oversold status --- from May 17's high $6.72 to yesterday's Super-Ridiculous-Low price $1.08!

This Diamond_In_Rough has Shocking Huge Positive Book Value (BV) --- $36.22 a share which is 33.54 Times of Super-Ridiculous-Low price $1.08! Also it has Huge Positive Cash Value (CV) --- $2.36 a share which is 2.19 Times of Super-Ridiculous-Low price $1.08!

That means that TNXP is Super Undervalued now! Easy to surge over May 17's high $6.72 very soon!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

There is a 3.1-Bagger Huge Price-Gap between $3.84 and today's Temporary high $1.24! So, TNXP will run a 5.2-Bagger+ Easy & Quick Rally again in the coming days/weeks!

Note, the 50-Day Moving-Average-Line (MAL) is at $5.13 from the first chart below!

Hopefully as soon as today or next week the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger+ Huge Rally...

The current Market Value is Super-Ridiculous-Low --- Mere $3M based on Super Tiny OS count!

Yes, 1:32 R/S on June 10. Before the R/S, the 52-week-low was slightly higher than $0.1 or Post-R/S's $3.2. There is a 3.2-Bagger huge gap between $3.84 (i.e. Pre-R/S's $0.12) and yesterday's high $1.2! So, we'll soon see a 5.2-Bagger Easy & Quick Rally again just like TNXP did in last January from the fourth chart below!

Note, the 50-Day MAL is at $5.23 from the first chart below!

Today I took a initial starting position as I said yesterday because the whole dilution is already completely done today (which is also the company planned) based on the past three day's total trading volumes (7.75M shares) is far beyond the Entire old OS (2.98M shares) plus All the new offerings (3.75M shares)! Which is a very good news since no more diluting sale other than some weak hand's small selling starting from tomorrow!

https://www.otcmarkets.com/filing/html?id=17616367&guid=1qQ-knrHt-zG-hh

Hopefully as soon as tomorrow or next week the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger Huge Rally again...

I'll hold and add more dirt cheap shares to see if this Hidden Gem will test May 17's high $6.72 again?

It seems that the new dilution (3,753,558 shares) is already done today because today's trading volume (5,177,940 shares) is over 1.734221 Times of the Entire old OS count (2,985,744 shares) here! Also last evening session there was over 700K shares sold by the old shareholders. So, the total trading volumes after yesterday's dilution news is about Double of the Entire old OS count!

Also in the After-Hour session, the price did bounce up to daily-high $1.2 right before the evening session close!

Thus, the current new FIXED OS should be total 6,739,302 shares.

Therefore, tomorrow I'll take a initial long position before TNXP soars 5.2-Bagger again or even 6.222222-Bagger to test May 17's high $6.72 in the coming days/weeks...

Big move here dudes!! RNAZ Monster move baby!!!

The R/S stunt was to satisfy the Naz listing. Thats not a good reason in my mind to pull such a stunt. Go to the otc with the other bio start ups.

I see it as a vanity stunt ad more of the drug accomplishments. Yes funding is easier, but institutional investors see better than any one when it's become desperate.

I'd rather have my cash in a VT&GN's pipeline.

You are right, it is all the retail shareholder's bailing due to too large losses since the new dilution is not started yet! Can we expect TNXP to soar 5.2-Bagger again to surge over its most recent high $5.616 like it did in January of 2023 (5.2-Bagger Quick Rally from Pre-R/S $0.28 to $1.456 Within Less Than A Month from the second chart below) in the coming days/weeks?

Note, the most recent high was $6.72 from the first chart below!

With only 2,985,744 shares of Super Tiny OS count how could TNXP be traded at near 2.5M shares so far? I bet Huge (Naked)-Shorting activities are going on here now which will cause Huge Shorting-Squeezing very soon...

So, I will take a long position as soon as today since the price is too cheap to be missed out.

OFFERING at $1.06!

Bwahahahahahah

bidding 15 cents here

UNBELIEVABLE SELLING

TNXP new 52 week low

Is it diluting or retail bailing?

They need to let this go to the OTC

Another New 52-week-low $1.83 was just created this early morning! What an ENDLESS Super-Heavy Diluting Pos Scam! I bet this trash stock will test $1 as soon as this week...

Depends on how far retail takes it.

The biggest question, can the Company justify The market cap.
It might be destined for the OTC anyways.
I wonder why they didn't go a bigger R/S?

Pharma is a money and time drain. Risk is always too high for those elusive FDA approvals.,

They have to save their Naz listing. Thats the biggest fire.
Might be an OTC after all.
An OTC with a low float.

$2.26 so far! Where is the Bottom with the ENDLESS Super-Heavy Dilutions?

Was there a reverse split? .......Thanks!!!

Your going to $3.20
Real fast.

I just hope the knee jerk sell off is over.
Then they can get back to business

Is it possible to see $0.3 again in the near future? Why the ENDLESS Super-Heavy Dilutions here? Can we expect the dilution to be stopped in the future?

Will it further crash to $0.05 or it will bounce back to $0.21 again?

Is $0.1 the Bottom?

TNXP 10Q due 3/26

TNXP 10Q due 3/19

I don't know man, but getting to phase 3 can burn through an A/S
Pharma plays are a time suck and all hinges on the FDA.
I like the price, O/S and treatment targets.

I'd love to see it dip below .30 gain
I'll think about a starter then.



https://finance.yahoo.com/news/tonix-drug-shown-relieve-pain-130000206.html

TNXP = Lifestyle company with periodic pump & dump spike.. well coordinated with friendly broker house. Rince - Roll Back - Repeat.. you loose all your money staying in.. Management is getting fat at the expense of skinny bag holders who drink tonix poison coo-laid

MARKET CAP 9 MIL AND GOT 30 MIL UP FRONT PLUS 114 MIL LATER. 144 MIL VS 9 MIL MARKET CAP

43000 SHARE BUY. INSTITUTIONAL INVESTORS PAYING 55 CENTS . PRICE 37 CENTS

Hope is not a strategy. Read today abortion news. It makes you want to vomit again & again

Monster will take all your remaining pennies. This is going to 0

Classic abortion! This is classic pump&dump shame designed & executed in cold blood by horrible management team. One look at company chart with history of roll backs said it all. Charts don’t lie - people do. Buyer be aware of to-nix scam!

Today’s study news is great. I guess the offering announced…not so much.